|  |  | 

India Top Headlines

Monoclonal antibodies to treat Covid patients should always be used in pairs to minimize mutation formation: Ex ICMR DG | India News


NEW DELHI: Monoclonal antibodies, recently introduced in India as an antibody therapy to treat Covid-positive patients, are being used to minimize mutation formation and should always be used in pairs, said former CEO Dr. Nirmal K Ganguly from India. Council for Medical Research (ICMR) on Monday.
When one is used alone, it causes a lot of mutation in the virus, so a cocktail is used to minimize the formation of mutations and is therefore always used in pairs, Dr. Ganguly told ANI, adding that it prevents that the spike protein binds to the s2 receptor and the integrin receptor beta.
“Plasma therapy, which differs in quality and quantity, has been deprecated and monoclonal antibodies have been introduced, which are made in very high concentrations and tested to neutralize access to see how efficient they are. Essentially, these monoclonal antibodies prevent that the spike proteins bind to the s2 receptor and the beta integrin receptor, “he said.
Citing the ineffectiveness in the number of new cases under the ICMR guidelines, he supported the removal of the use of the convalescent plasma theory from the recommended treatment protocols for Covid-19.
The expert, while talking about how antibody therapy works, explained: “The monoclonal antibody works against the target epitope, against the proteins of the virus that are in the peak region and against that particular domain, just to know how they are. reacting specifically. ”
The monoclonal antibodies available against the spike protein are IGGI, which is very specific and homogeneous, says the expert.
These antibodies are made in the laboratory and are specifically designed to fight the disease they treat. The artificial process by which monoclonal antibodies are made is a fermentation process in which some vials are produced.
“Monoclonal antibodies function as if they were made against the targeted epitope. There are six sites in the receptor-binding domain that are important in the spike protein, which undergo functional mutation / enhancement to create a specific monoclonal antibody,” said Dr. Ganguly.
Monoclonal antibody therapy was recently approved in India. The first person to be given the antibody therapy was an 84-year-old Covid-positive patient in Gurgaon who returned home after treatment on May 27.
He has become the first person in India to receive the COVID drug cocktail, which came into the limelight after it was administered to former US President Donald Trump when he tested positive for the virus last year. past.
This FDA-approved therapy demonstrated good efficacy in phase 1/2 and phase 3 studies, reducing Covid-19-related hospitalization and death by 70 percent. Approved by the Comptroller General of Medicines of India (DCGI), this single-dose infusion-based treatment can be provided on an outpatient basis or in a daycare setting and marks a dramatic shift in coronavirus care in India.

Original source